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In the presence of a procoagulant membrane surface and
divalent metal ions, factor Va (fVa)3 binds factor Xa (fXa) to
form prothrombinase. Prothrombinase is the two-subunit
enzymatic complex where the non-enzymatic regulatory subunit (fVa) controls the rate and directs cleavage of prothrombin
(FII) by the catalytic subunit (fXa) at two spatially distinct sites
resulting in timely ␣-thrombin (IIa) formation at the place of
vascular injury (1–3). Cleavage at Arg271 and Arg320 of FII is
required to form the active serine protease IIa. The essential IIa
molecule bears strong homology with other serine protease
enzymes, such as activated protein C (APC), chymotrypsin, and
fXa. Several different numberings of IIa residues appear in the
literature based on either the chymotrypsin numbering (4) or
IIa numbering (5, 6) or the entire FII sequence (7). The latter
nomenclature is used herein with the appropriate chymotrypsin numbering in parentheses when required for comparison
with the existing data in the literature.
Historically, it has been shown that in the absence of fVa,
initial cleavage at Arg271 of FII results in the generation of the
inactive intermediate prethrombin-2 and fragment 1䡠2. Further
cleavage of prethrombin-2 at Arg320 generates IIa (prethrombin-2 pathway) (8 –21). Concurrent with the appearance of
excess fVa during clotting and in the presence of a procoagulant
surface, the order of cleavages is reversed, and initial cleavage at
Arg320 generates a transient enzymatically active intermediate,
meizothrombin, that has much higher catalytic efficiency than
IIa toward chromogenic substrates usually employed to assess
IIa activity (18, 22–24). Meizothrombin is next cleaved at
Arg271 resulting in the generation of IIa and fragment 1䡠2
(meizothrombin pathway). Although efficient cleavage at each
site requires the presence of phospholipids, initial cleavage at
Arg320 is entirely fVa-dependent.
In the absence of fVa, the two activation cleavage sites are not
readily available, and FII is activated at a slow non-physiological
rate by membrane-bound fXa alone. Interactions between fXa
and FII are known to exist in the presence and absence of fVa;
however, the enhanced activity of fXa within prothrombinase
toward both activating cleavage sites is controlled solely by the
membrane-bound non-enzymatic cofactor (3, 16, 17, 25, 26).
3

The abbreviations used are: fVa, factor Va; fV, factor V; FII, prothrombin; fXa,
factor Xa; IIa, ␣-thrombin; r, recombinant; PC, L-␣-phosphatidylcholine;
PCPS, small unilamellar phospholipids vesicles composed of 75% PC and
25% L-␣-phosphatidylserine (w/w); rFIIWT, recombinant wild type human
prothrombin; rIIaWT recombinant wild type human ␣-thrombin; fVIII, factor
VIII; DAPA, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide; ABE, anionbinding (pro)exosite; APC, activated protein C; TP, prothrombin time.
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Prothrombin (FII) is activated to ␣-thrombin (IIa) by prothrombinase. Prothrombinase is composed of a catalytic subunit, factor Xa (fXa), and a regulatory subunit, factor Va (fVa),
assembled on a membrane surface in the presence of divalent
metal ions. We constructed, expressed, and purified several
mutated recombinant FII (rFII) molecules within the previously
determined fVa-dependent binding site for fXa (amino acid
region 473– 487 of FII). rFII molecules bearing overlapping
deletions within this significant region first established the minimal stretch of amino acids required for the fVa-dependent recognition exosite for fXa in prothrombinase within the amino
acid sequence Ser478–Val479–Leu480–Gln481–Val482. Single,
double, and triple point mutations within this stretch of rFII
allowed for the identification of Leu480 and Gln481 as the two
essential amino acids responsible for the enhanced activation of
FII by prothrombinase. Unanticipated results demonstrated
that although recombinant wild type ␣-thrombin and rIIaS478A
were able to induce clotting and activate factor V and factor VIII
with rates similar to the plasma-derived molecule, rIIaSLQ3AAA
with mutations S478A/L480A/Q481A was deficient in clotting
activity and unable to efficiently activate the pro-cofactors. This
molecule was also impaired in protein C activation. Similar
results were obtained with rIIa⌬SLQ (where rIIa⌬SLQ is recombinant human ␣-thrombin with amino acids Ser478/Leu480/Gln481
deleted). These data provide new evidence demonstrating that
amino acid sequence Leu480–Gln481: 1) is crucial for proper recognition of the fVa-dependent site(s) for fXa within prothrombinase on FII, required for efficient initial cleavage of FII at
Arg320; and 2) is compulsory for appropriate tethering of
fV, fVIII, and protein C required for their timely activation
by IIa.
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ings from our laboratory (47– 49). A very recent model of prothrombinase using as a template the crystal structure of
prothrombinase from the snake venom of Pseudonaja textilis
verified and established the critical role of the acidic COOHterminal region of fVa heavy chain for optimal rates of FII cleavage at two spatially distinct sites by prothrombinase resulting in
timely IIa formation at the place of vascular injury (27, 55).
Additional studies with several recombinant prethrombin-1
molecules, where seven critical basic amino acids within (pro)
exosite I were individually changed to glutamic acid, confirmed
the interaction of (pro)exosite I with fVa acidic regions (50).
Notably, the data revealed that although mutated prethrombin-1 is a poor substrate for prothrombinase, the same molecule was activated by membrane-bound fXa alone with similar
rates as wild type prethrombin-1. Supplementary to these studies, Yegneswaran et al. (56), utilizing synthetic peptide derived
from a highly conserved region of FII, postulated the existence
of an fVa-dependent binding exosite for fXa within the
sequence 473– 487 of FII (chymotrypsin numbering 149D-163
(4)) that is in close spatial arrangement to (pro)exosite I. The
same authors have also identified an fVa-independent site for
fXa on prothrombin (amino acids 557–571) (57).
This study was initiated to identify and investigate the identity and role of the minimum required amino acid stretch
within sequence 473– 487 of FII that is conserved in a wide
range of mammalian species and regulates peptide bond specificity and FII activation by prothrombinase in an fVa-dependent manner. Our findings identify for the first time two specific amino acids within FII that have a dual role. They are
required for efficient fVa-dependent tethering of fXa needed
for timely FII cleavage at Arg320 and IIa formation, while also
serving an important role in directing efficient cleavage of IIa’s
physiological substrates. The latter is a prerequisite for expression of optimal physiological IIa activity.

Experimental Procedures
Materials—Phenylmethylsulfonyl fluoride (PMSF), o-phenylenediamine dihydrochloride, Hepes, Trizma (Tris base), and
Coomassie Blue R-250 were purchased from Sigma. fV-deficient plasma was purchased from Research Protein Inc. (Essex
Junction, VT). Secondary anti-mouse, anti-sheep, and antiequine IgG coupled to peroxidase were from Southern Biotechnology Associates, Inc. (Birmingham, AL). L-␣-Phosphatidylserine (PS) and L-␣-phosphatidylcholine (PC) were from Avanti
Polar Lipids (Alabaster, AL). Chemiluminescent reagent ECL
Plus, heparin-Sepharose, and Mono Q 5/50 columns were from
GE Healthcare. Normal reference plasma and chromogenic
substrate Spectrozyme-TH were from American Diagnostica
Inc. (Greenwich, CT). S-2238 was from AnaSpec (Fremont,
CA); recombiPlasTin used in the clotting assays was purchased
from Instrumentation Laboratory Co. (Lexington, MA). The
reversible fluorescent IIa inhibitor dansylarginine-N-(3-ethyl1,5-pentanediyl)amide (DAPA), human plasma-derived protein C, human plasma-derived IIa, human plasma-derived FII,
and FII-deficient plasma were purchased from Hematologic
Technologies Inc. (Essex Junction, VT). The purified human
plasma-derived protein C preparation used contained both
heavy chain isoforms that are activated to APC with similar
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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Consequently, the innate process of coagulation rests on specific molecular interactions involved in the fVa-dependent activation of FII by prothrombinase. In relation to fXa alone, the
relative rate of IIa formation by prothrombinase is increased by
300,000-fold because of the increase in the rates of both FII
cleavages. This increase is mainly associated with a large (3,000fold) increase in the kcat value of fXa within prothrombinase
with a 100-fold decrease in the Km value of the enzyme (16).
This substantial increase in enzymatic activity resulting in rapid
and physiologically relevant IIa generation at the place of vascular injury is credited through precise and unique interactions
of the cofactor with specific amino acids affiliated with both
membrane-bound fXa and membrane-bound FII as recently
demonstrated (27). Accordingly, the introduction of the nonenzymatic cofactor into prothrombinase equips the organism’s
coagulation artillery necessary for the explosive arrest of vasculature bleeding.
Factor V (fV) is a large quiescent multidomain (A1-A2-B-A3C1-C2) protein that circulates in blood at a concentration of 20
nM (28 –31). Three sequential cleavages of fV at Arg709, Arg1018,
and Arg1545 (29, 32–34) by IIa and/or fXa (35, 36) release the B
domain and promote formation of the active cofactor fVa. FII
circulates abundantly in blood at a concentration of 1.4 M as
the zymogen form of the serine protease IIa (7, 37). Mature FII
protein is composed of a region containing several post-translationally modified ␥-carboxyglutamic acid residues (described
as the Gla domain, residues 1– 46), followed by two Kringle
domains (residues 65–143 and 170 –248, respectively) and a
serine protease domain (residues 272–579, see Fig. 1). FII contains three linkers as follows: linker 1 (residues 47– 64) connects the Gla domain to kringle-1; linker 2 (residues 144 –169)
connects the two kringles; and linker 3 (residues 249 –284) connects kringle-2 to the A-chain portion of IIa (7, 38) (Fig. 1).
The necessary fVa-dependent activation of FII by prothrombinase is a widely studied mechanism of coagulation but is still
poorly understood. Numerous fVa-binding sites are acknowledged to exist on FII. Earlier investigations have shown the
existence of binding sites on FII for fVa in each of the kringle
domains (39 – 41) and within the Gla domain (42). Furthermore, significant protein-protein interactions between the
acidic COOH-terminal region of fVa and a region rich in basic
amino acids of FII have been inferred and characterized indirectly by employing molecular techniques involving specific
hirudin-like ligands and the anion-binding (pro)exosite I (ABE
I) of FII derivatives, as well as directly using a specific acidic
peptide derived from the COOH-terminal region of the fVa
heavy chain and recombinant fVa molecules (43– 49). Site-directed mutagenesis of the basic residues in the proenzyme generated a recombinant FII molecule impaired in its ability to be
activated by fully assembled prothrombinase (50). Although a
crystal structure and a model of fVa have been available for
some time now (51, 52), the crucial interaction of the acidic
hirudin-like COOH-terminal portion of the heavy chain of the
cofactor with FII required for efficient IIa formation was initially ignored because it was missing from the crystal structure
of the cofactor (51). This interaction was further discounted
without providing any solid evidence (53) despite initial findings by Guinto and Esmon (54) and more recent original find-
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478 – 482 several point mutations were made based on amino
acid solvent exposure and homology within other proteins. The
first rFII point alanine mutation rFIIS478A was constructed
using the mutagenic primers 5⬘-GGT AAG GGG CAG CCC
GCA GTC CTG CAG GTG-3⬘ (sense) and 5⬘-CAC CTG CAG
GAC TGC GGG CTG CCC CTT ACC-3⬘ (antisense) (corresponding to the S478A mutation). The next single point mutation rFIIL480A was constructed using the mutagenic primers 5⬘GGG CAG CCC AGT GTC GCG CAG GTG GTG AAC CTG
CCC-3⬘ (sense) and 5⬘-GGG CAG GTT CAC CAC CTG CGC
GAC ACT GGG CTG CCC-3⬘ (antisense) (corresponding to
the L480A mutation). In addition to single point mutations, we
constructed two double alanine mutations, rFIISL3AA and
rFIISQ3AA, within the stretch 478 – 482 of FII. For rFIISL3AA,
we used the mutagenic primers 5⬘-GGT AAG GGG CAG CCC
GCA GTC GCG CAG GTG GTG AAC CTG-3⬘ (sense) and
5⬘-CAG GTT CAC CAC CTG CGC CAC TGC GGG CTG
CCC CTT ACC-3⬘ (antisense) (corresponding to the S478A/
L480A mutation). Also, for rFIISQ3AA (where rFIISQ3AA is
recombinant human prothrombin with the mutation S478A/
Q481A), we used the mutagenic primers 5⬘-GGT AAG GGG
CAG CCC GCA GTC CTG GCG GTG GTG AAC CTG-3⬘
(sense) and 5⬘-CAG GTT CAC CAC CGC CAG GAC TGC
GGG CTG CCC CTT ACC-3⬘ (antisense) (corresponding to
the S478A/Q481A mutation). Finally, we constructed a rFII
molecule with a triple mutation, rFIISLQ3AAA with the mutagenic primers 5⬘-GGT AAG GGG CAG CCC GCA GTC GCG
GCG GTG GTG AAC CTG-3⬘ (sense) and 5⬘-CAG GTT CAC
CAC CGC CGC GAC TGC GGG CTG CCC CTT ACC-3⬘
(antisense) (corresponding to the S478A/L480A/Q481A mutation) and an rFII molecule with Ser478/Leu480/Gln481 deleted
(rFII⌬SLQ) using the mutagenic primers 5⬘-GGT AAG GGG
CAG CCC GTC GTG GTG AAC CTG CCC-3⬘ (sense) and
5⬘-GGG CAG GTT CAC CAC GAC GGG CTG CCC CTT
ACC-3⬘ (antisense). All deletions and point mutations were
confirmed by DNA sequencing (DNA Analysis Facility, Department of Molecular Cardiology, The Lerner Research Institute,
Cleveland Clinic).
Expression of Wild Type and Mutant rFII Molecules in Mammalian Cells—rFII expression in baby hamster kidney (BHK21) cells has been described previously in detail (63). Briefly,
BHK-21 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with fetal bovine serum
(10%), and a streptomycin/penicillin (1%) mixture. Isolated
plasmids (4 – 6 g) for wild type and mutant rFII molecules
were transfected into the BHK-21 cells using a lipid-based
transfection reagent, Lipofectamine (Invitrogen), according to
the manufacturer’s instructions. Following an incubation
period of 48 h, DMEM was supplemented with fetal bovine
serum (10%), streptomycin/penicillin (1%) mixture, and methotrexate (1 M) and added to the cells. After 3 weeks of treatment with the selection medium, colonies were isolated, grown,
and screened for levels of rFII expression by Western blot analysis using a monoclonal antibody and compared with plasmaderived FII as a standard (1 g/ml). Identification of the highest
secreting rFII clone was further used in large scale protein
expression with serum-free Opti-MEM supplemented with
ZnCl2 (50 M), vitamin K1 (10 g/ml), and penicillin/streptoJOURNAL OF BIOLOGICAL CHEMISTRY
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rates as described earlier (58, 59). Human fXa was purchased
from Enzyme Research Laboratories (South Bend, IN). The
plasmid pZEM229R-lite encoding human recombinant prothrombin (rFII) was a generous gift from Dr. Kathleen Berkner
(Cleveland Clinic Foundation, Cleveland, OH). QuikChange威
II XL site-directed mutagenesis kit was obtained from Agilent
Technologies Genomics (Santa Clara, CA). All molecular biology and tissue culture reagents, specific primers, and medium
were obtained from Gibco, Invitrogen, or as indicated. Monoclonal antibodies to fV (␣HFVHC17 and ␣HFVLC9), monoclonal antibody ␣HFV1 coupled to Sepharose used to purify
plasma and recombinant fV molecules, and a polyclonal antibody to FII used for immunoblotting experiments during rFII
production were provided by Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont, Burlington).
Plasma factor V (fVplasma) and plasma fVa (fVaplasma) were purified as described previously (60 – 62).
Construction of rFII Molecules—To investigate the importance of amino acid region 473– 487 of the serine protease
domain of FII, we first constructed a recombinant mutant FII
molecule with this region deleted (rFII⌬473– 487) using Stratagene’s QuikChange威 site-directed mutagenesis kit and the
pZEM229R-lite plasmid. rFII⌬473– 487 was constructed using
the mutagenic primers 5⬘-GAG ACG TGG ACA GCC AAC
GTT GTG GAG CGG CCG GTC TGC AAG-3⬘ (sense) and
5⬘-CTT GCA GAC CGG CCG CTC CAC AAC GTT GGC
TGT CCA CGT CTC-3⬘ (antisense) (corresponding to the
473
GKGQPSVLQVVNLPI487 deletion). The mutation was confirmed by DNA sequencing (DNA Analysis Facility, Department of Molecular Cardiology at The Learner Research Institute, Cleveland Clinic). To further investigate the minimum
sequence of amino acids required for the fVa-dependent fXa
binding on FII within the region 473– 487 of the serine protease
domain, several rFII molecules with the mutations denoted as
rFII⌬N10 (rFII⌬N10 is recombinant human prothrombin missing
amino acids GKGQPSVLQV), rFII⌬C10, rFII⌬S5V, rFIIS478A
(rFIIS478A is recombinant human prothrombin with the
mutation S478A), rFIIL480A, rFIISL3AA, rFIISQ3AA, and
rFIISLQ3AAA (where rFIISLQ3AA is recombinant human prothrombin with the mutation S478A/L480A/Q481A) were
constructed using Stratagene’s QuikChange威 site-directed mutagenesis kit and the pZEM229R-lite plasmid. First, overlapping deletions in the region 473– 487 were constructed using
the mutagenic primers for rFII⌬N10 5⬘-G ACG TGG ACA GCC
AAC GTT GTG AAC CTG CCC ATT GTG GAG-3⬘ (sense)
and 5⬘-CTC CAC AAT GGG CAG GTT CAC AAC GTT GGC
TGT CCA CGT C-3⬘ (antisense) (corresponding to the
473
GKGQPSVLQV482 deletion), whereas mutagenic primers
used for rFII⌬C10 were 5⬘-GTT GGT AAG GGG CAG CCC
GTG GAG CGG CCG GTC TGC-3⬘ (sense) and 5⬘-GCA GAC
CGG CCG CTC CAC GGG CTG CCC CTT ACC AAC-3⬘
(antisense) (corresponding to the 478SVLQVVNLPI487 deletion). Similarly, the middle deletion of the overlapping mutations rFII⌬S5V was constructed using the mutagenic primers 5⬘GTT GGT AAG GGG CAG CCC GTG AAC CTG CCC ATT
GTG-3⬘ (sense) and 5⬘-CAC AAT GGG CAG GTT CAC GGG
CTG CCC CTT ACC AAC-3⬘ (antisense) (corresponding to
the 478SVLQV482 middle deletion). Next, within the sequence
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digestion of the B chain of IIa obtained from ExPASy/SwissProt and verified the existence of the deletion in rFII⌬473– 487.
Similar experimental work performed with some other mutant
molecules demonstrated that the rFII molecules described
herein are fully carboxylated, can be appropriately processed by
prothrombinase and fXa alone, and do indeed contain the
expected deletion/mutations.
Gel Electrophoresis, Western Blotting, and Amino Acid
Sequence from PVDF Membranes—SDS-PAGE was performed
according to the method of Laemmli (66), using 9.5% gels following reduction with 2% ␤-mercaptoethanol. Screening for
high levels of rFII-secreting clones was performed by Western
blotting using PVDF according to a modified method initially
described by Towbin et al. (67). Successfully transferred proteins were visualized by chemiluminescence using ECL Plus
reagents following incubation with a polyclonal antibody specific to prethrombin-1. In some experiments, proteins were
transferred to PVDF membranes and stained with Coomassie
Blue, and NH2-terminal sequencing analysis was performed at
the Biomolecular Resource Facility at the University of Texas
Medical Branch (Galveston TX) as described previously in
detail by our laboratory (68).
Studies of the Pathway for FII Activation by Gel Electrophoresis—The investigation of the activation rates of plasmaderived and of all rFII molecules, cleavage and activation by fXa
alone or prothrombinase was performed according to a protocol previously described by our laboratory using plasma-derived FII or rFII (47, 49, 69). The calculation of the rates of all FII
molecules consumption by fXa alone or by prothrombinase
were performed as described previously with the software
Prizm (GraphPad) (47, 49, 69).
Kinetic Titrations of Prothrombinase—To investigate the
kinetic constants (Km and kcat) of prothrombinase, assays with a
set amount of plasma-derived fVa and fXa (as described in the
legend to the figures) were executed as described by our laboratory in many instances (47, 49, 69, 70). The initial rate of IIa
generation was analyzed with the software Prizm (GraphPad)
according to the Michaelis-Menten equation, and all final numbers reported are derived directly from the graphs. Each experiment used to report final numbers was run at least in duplicate,
and the goodness of fit (R2) for every model tested is provided
under the “Results.” The change in transition-state stabilization
free energy, which measures the effect of the mutations in rFII,
was calculated for the double and triple mutants as extensively
detailed in the literature and previously reported by our laboratory (71–77).
Recombinant Thrombin Activity—rFII molecules were converted to rIIa by 1 nM prothrombinase. Full conversion of rFII to
rIIa under these conditions was verified by gel electrophoresis.
The chromogenic substrate S-2238 was used to assess rIIa
activity by employing serial dilutions of the enzyme in TrisNaCl buffer in the presence of 0.1% PEG 8000. The final concentrations of S-2238 used in the reactions were 0.94, 1.87, 3.75,
7.50, 15, and 60 M. The reaction was started by the addition of
4 nM rIIa. The data were obtained at 1 min using a SpectraMax
M2 plate reader (Molecular Devices). The optical density was
automatically adjusted for a 1-cm pathlength, and the Vmax was
calculated from the optical density using the established extincVOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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mycin/Fungizone (1% v/v) mixture, and the medium were collected every 2 days for 2–3 weeks. Following collection, the
media were stored at ⫺80 °C until the desired amount (usually
4 liters) was obtained and used for purification.
Purification of rFII Molecules—Purification of rFII was performed through a well established protocol previously
described in detail (63). Briefly, collected media were thawed,
filtered (0.45 m), and loaded on a tandem column setup of
Amberlite XAD2 and Q-Sepharose. Following the complete
addition of medium to the two columns, the Q-Sepharose column was separated and washed with TBS (0.02 M Tris, 150 mM
NaCl, pH 7.4). The bound material containing rFII on the
Q-Sepharose was eluted with 0.02 M Tris, 0.5 M NaCl, pH 7.4.
The material was treated with barium citrate, and the isolated
pellet was dissolved in a minimum volume of EDTA (0.5 M, pH
7.4). The dissolved pellet was dialyzed twice in fresh TBS (two
times, 4 liters) and filtered (0.45 m) prior to being loaded onto
a General Electric FPLC instrument, equipped with a strong
anionic exchanger Mono Q 5/50 column. The column was
equilibrated in TBS, and a stepwise gradient of calcium (0 –50
mM) in TBS was used to isolate fully ␥-carboxylated rFII. Tubes
containing the rFII molecules were concentrated using an
appropriate Millipore Centricon (Billerica, MA), and aliquots
were frozen at ⫺80 °C to avoid repeated freeze-thaw cycles.
Following purification and before any experiment, all rFII molecules were characterized as extensively described below.
The level of ␥-carboxylation of all rFII molecules was determined at the Protein Chemistry Facility, Texas A&M University, by alkaline hydrolysis followed by amino acid analysis as
described (64, 65). All purified molecules were found to be
properly carboxylated (Table 1). To verify that rFIIWT and
rFII⌬473– 487 are processed at the appropriate cleavage sites
when incubated with prothrombinase or fXa alone and produced the expected fragments, the recombinant proteins were
incubated with PCPS vesicles and fXa in the presence and
absence of fVa. Following gel electrophoresis, fragments were
identified following NH2-terminal sequencing from PVDF
membranes (see below). All fragments derived from the recombinant FII molecules have the expected NH2-terminal sequence
following cleavage by either prothrombinase or membranebound fXa alone (data not shown).
The fact that the rFII⌬473– 487 molecule contains a 15-amino
acid deletion was verified by cDNA sequencing. However, in
view of the surprising and unexpected data presented herein, it
was important to confirm the existence of the deletion in the
purified recombinant protein. This was accomplished by mass
spectrometry. Briefly, following activation of rFII⌬473– 487 and
FIIplasma by prothrombinase, aliquots were analyzed in triplicate under reducing conditions on an SDS-12% PAGE. Following staining/destaining, the B-chain of ⌱⌱a was excised from the
gel, and the proteins were reduced and alkylated with iodoacetamide. Digestion (in gel) was accomplished with porcine
trypsin. Analysis of the resulting peptides was performed with
an ␣-cyanohydroxycinnamic acid (matrix) Kratos Axima CFR
MALDI-TOF mass spectrometer (reflector mode; 25,000 accelerating voltage) in the Protein Chemistry Laboratory, Texas A
& M University, under the direction of Dr. Larry Dangott. The
data obtained were compared with the peptide map following
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Results
rFII Expression—To evaluate the minimal amino acid
sequence necessary for the fVa-dependent FII activation by
prothrombinase within the 473– 487 critical amino acid stretch
of FII, we stably transfected BHK-21 cell lines according to a
previously well defined protocol (63) with several constructs.
Mutant rFII molecules prepared were as follows: rFII⌬473– 487
(missing residues 473GKGQPSVLQVVNLPI487), rFII⌬N10
(missing amino acid residues 473GKGQPSVLQV482), and
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

FIGURE 1. Schematic of FII. FII is converted to IIa through two fXa-catalyzed
cleavages at Arg271 and at Arg320 resulting in IIa formation. The red rectangle
denotes the fVa-independent site for fXa on FII (57), and the yellow rectangle
represents the fVa-dependent site for fXa (56, 95) studied herein. The light
blue rectangle denotes the amino acids composing (pro)exosite I (50). All
mutants created, stably transfected, purified to homogeneity, and used in the
study are shown together with their assigned name used throughout this
work.

rFII⌬C10 (missing amino acid residues 478SVLQVVNLPI487)
(Fig. 1). These three mutant molecules have five amino acids in
common (478SVLQV482). We thus proceeded to construct, stably express, and purify to homogeneity rFII⌬S5V (a rFII molecule missing amino acids 478SVLQV482) (Fig. 1). Preliminary
experiments with rFII⌬S5V demonstrated that the mutant molecule had no clotting activity similarly to rFII⌬473– 487, rFII⌬N10,
and rFII⌬C10. We next proceeded to make single, double, and
triple alanine substitutions within this significant region.
The following recombinant mutant molecules were made:
rFIIS478A (S478A), rFIIL480A (L480A), rFIISL3AA (S478A/
L480A), rFIISQ3AA (S478A/Q481A), and rFIISLQ3AAA (S478A/
L480A/Q481A) (Fig. 1). It is important to note that rIIaS478A
(where rIIaS478A is recombinant human ␣-thrombin with the
mutation S478A) was previously tested and found to behave as
rIIaWT (5, 6). We have thus used this mutation as an internal
control for all double and triple alanine substitutions of rFII.
Finally, and to verify the results obtained with rFIISLQ3AAA, we
have also made an rFII molecule with these three amino acids
deleted (rFII⌬SLQ). In all experiments, results with the mutant
molecules were compared with results obtained with rFIIWT or
FIIplasma.
Prothrombin Time—The ability of FII and all rFII molecules
to be activated under physiological conditions and to promote
fibrin clot formation was first assessed using prothrombin
times (PTs) (Fig. 2). The results shown in Table 1 demonstrate
that although FIIplasma, rFIIWT, and rFIIS478A had comparable
clotting times of 12.7, 12.2, and 11.7 s, respectively, rFIIL480A
(where rIIaL480A is recombinant human ␣-thrombin with the
mutation L480A) exhibited a minimal but significant prolonged PT of ⬃30 s (Fig. 2). Surprisingly, although rFIISL3AA
(where rFIISL3AA is recombinant human prothrombin with the
mutation S478A/L480A) and rFIISQ3AA had slow but compaJOURNAL OF BIOLOGICAL CHEMISTRY
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tion coefficient of S-2238 at room temperature (78) following
plotting of the data to the Michaelis-Menten equation using the
software Prizm (GraphPad).
Activation of fV and fVIII by rIIa—rFII molecules were converted to rIIa by 1 nM prothrombinase. Full conversion of rFII to
rIIa under the conditions described was assessed by gel electrophoresis. The resulting wild type and mutant rIIa were assessed
for their ability to cleave and activate the cofactors over time, by
SDS-PAGE. Reaction mixtures containing either 500 nM plasma-derived human fV or recombinant human fVIII were
diluted in Tris-NaCl buffer in the presence of Ca2⫹. The final
concentration of rIIa in the mixtures was 4 nM.
Activation of Protein C by Plasma-derived IIa or rIIa—rFII
molecules described herein were converted to IIa by 1 nM prothrombinase. Full conversion of rFII to rIIa under the conditions described was assessed by gel electrophoresis. The resulting IIa molecules were assessed for their ability to cleave and
activate protein C in the presence of thrombomodulin and
PCPS vesicles according to a procedure previously described
(79) in Tris-buffered saline with Ca2⫹. Protein C activation was
verified by SDS-PAGE under reducing conditions. The final
concentration of IIa in all mixtures was 8 nM. Gels were stained
with Coomassie Brilliant Blue.
FII Clotting Assay—To assess the function of all FII molecules
in whole plasma, a clotting assay using FII-deficient plasma
was employed. The clotting assay was performed as
described previously (80), and the time needed for formation
of a fibrin clot was monitored at 37 °C using a Diagnostica
Stago STart威 4 hemostasis analyzer as described previously
(80). The analyzer was set up to automatically measure the
time to clot up to 120 s.
Structural Analysis—To evaluate the structural features of
the Ser478, Leu480, and Gln481 residues, crystal structures of FII
and IIa were superimposed and compared. The three human
FII crystal structures that have been reported, show similar
conformations for the residues of interest and neighboring
regions; the highest resolution of these structures was chosen
for detailed analysis (38). From the many human IIa crystal
structures that are available, several representative examples in
different bound states were compared and found to have similar conformations for the region containing the residues of
interest. A high resolution structure of unbound IIa was chosen
as the representative structure for detailed analysis (81). The
program COOT was used to inspect structural features and
determine distances (82). AREAIMOL (83– 85) was used to calculate the solvent-accessible surface areas for specific residues,
and molecular figures were prepared with the PyMOL Molecular Graphics System, version 1.5.0.4 (Schrödinger, LLC).
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rable PTs of ⬃30 s, the triple mutant rFIISLQ3AAA was severely
ineffective in fibrin clot formation (PT ⬃116 s), whereas
rFII⌬SLQ (where rFII⌬SLQ is recombinant human prothrombin
with amino acids Ser478/Leu480/Gln481 deleted) had a PT
around 140 s (data not shown). In contrast, rFII⌬473– 487,
rFII⌬N10, rFII⌬C10, and rFII⌬S5V were unable to induce clotting
under the conditions described. These functional data demonstrate that either rFIISLQ3AAA or rFII⌬SLQ cannot get activated
to rIIa in a timely fashion, or that rIIaSLQ3AAA and/or rIIa⌬SLQ
formed are catalytically impaired because of the mutations, or
both. Because previous data have shown that the S478A transition in IIa is of no consequence for its chromogenic and proteolytic activity (5, 6), overall these results demonstrate for the
first time that both Leu480 and Gln481 have a profound effect on
IIa generation and/or IIa activity during fibrin clot formation or
both.
Activation of rFII Molecules—To ascertain the effect of
region 473– 487 of FII on its ability to be activated by membrane-bound fXa alone, in the absence of fVa, we assessed the
pattern of activation by gel electrophoresis over a 2-h time
period (Fig. 3). Fig. 3A shows a control experiment and demonstrates that FIIplasma activation by membrane-bound fXa alone
proceeds following initial cleavage at Arg271, through the intermediate prethrombin-2 with very slow gradual appearance of the
B-chain of IIa because of inefficient rate of cleavage at Arg320.
Surprisingly, with the removal of amino acids 473– 487 from
prothrombin (Fig. 3B), there is acceleration of rFII⌬473– 487 consumption through initial cleavage at Arg271 that is evident by
the prompt appearance of prethrombin-2. Additional examinations of the intensity of the B-chain of thrombin reveal a substantially delayed cleavage at Arg320 of rFII⌬473– 487 compared
with rFIIWT resulting in insignificant IIa generation. Scanning
densitometry of the gels shown in Fig. 3, A and B, showed that
the rate of rFII⌬473– 487 consumption by membrane-bound fXa
is ⬃4-fold increased compared with the rate of cleavage of
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FIGURE 2. Clotting activity of all forms of FII. The average clotting time
found in four different measurements in FII-deficient plasma is shown for all
FII/rFII molecules identified at the bottom of the graph.

rFIIplasma under similar experimental conditions (Table 1).
These data suggest that amino acid sequence 473– 487 of prothrombin provides a potential obstruction for efficient initial
cleavage of prothrombin at Arg271 by membrane-bound fXa
alone in the absence of fVa.
To further improve our understanding of the fundamental
role of amino acid region 473– 487 for FII activation by prothrombinase, we studied the pattern of FII activation by fully
assembled prothrombinase with gel electrophoresis over a 2-h
time period. A control experiment (Fig. 3C) demonstrates that
under the conditions used the activation of FIIplasma proceeds
efficiently following initial cleavage at Arg320, through the enzymatically active intermediate meizothrombin, as confirmed by
the appearance of fragment 1䡠2-A. Rapid cleavage of this fragment at Arg271 leads to the formation of IIa. In contrast, activation of rFII⌬473– 487 under similar experimental conditions is
significantly delayed through the same pathway as verified by
the late appearance of the B-chain of IIa (Fig. 3D). Scanning
densitometry of the gels shown in Fig. 3, C and D, showed that
rFII⌬473– 487 is consumed with a rate that is ⬃27-fold slower
compared with the rate of FIIplasma consumption or ⬃23-fold
slower compared with the rate of rFIIWT consumption under
the experimental conditions used (Table 1). These data suggest
that under conditions of saturating amounts of fVa with respect
to fXa, amino acid sequence 473– 487 of FII plays a preeminent
role because it is required for fast and efficient initial cleavage of
FII at Arg320 by prothrombinase.
To further investigate the effect of the deletions and point
mutations on rFII cleavage and activation by membrane-bound
fXa alone, we studied rFII activation by gel electrophoresis of all
mutants detailed in Fig. 1. Fig. 4A shows a control experiment
and demonstrates that rFIIWT activation by membrane-bound
fXa proceeds typically following initial cleavage at Arg271, as its
plasma counterpart through the intermediate prethrombin-2
with very slow and minimal appearance of the B chain of IIa
because of a nonproductive rate of cleavage at Arg320. With the
removal of amino acids 478 – 482 from rFII⌬S5V (Fig. 4B), there
is acceleration of rFII⌬478 – 482 consumption by fXa alone
through initial cleavage at Arg271 that is evident by the rapid
appearance of prethrombin-2. The fact that only trace amounts
of B-chain of IIa are apparent under the conditions employed
suggests a substantially deferred rate of cleavage at Arg320 of the
deletion mutant compared with cleavage of rFIIWT resulting in
insignificant amounts of IIa generation. Scanning densitometry
of similar gels shown in Fig. 4, A and B, showed that the rate of
consumption of all rFII molecules by membrane-bound fXa
alone is ⬃2.3– 8-fold increased compared with the rate of cleavage of rFIIWT or FIIPLASMA (Fig. 4C and Table 1). However,
although with rFIIS478A, rFIIL480A, rFIISL3AA, and rFIISQ3AA
minimal amounts of the B-chain of IIa are formed (data
not shown), when studying rFII⌬N10, rFII⌬C10, rFII⌬S5V,
rFIISLQ3AAA, and rFII⌬SLQ activation, there is accumulation of
prethrombin-2 with no significant amounts of B-chain of IIa
generated suggesting impaired cleavage of prethrombin-2 at
Arg320 by membrane-bound fXa (Fig. 4, B and D). These data
confirm our findings with rFII⌬473– 487 (Fig. 3) and reveal
that the dipeptide Leu480–Gln481 within the 15-amino acid
stretch 473– 487 of FII appears to be responsible for the sim-
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TABLE 1
Physical properties, clotting times, and rate of cleavage of various rFII molecules in the presence of a fixed concentration of membrane-bound
fXa or in the presence of prothrombinase
Mutant
FIIplasma
rFIIWT
rFII⌬473–487
rFII⌬N10
rFII⌬C10
rFII⌬S5V
rFIIS478A
rFIIL480A
rFIISL3AA
rFIISQ3AA
rFIISLQ3AAA
rFII⌬SLQ

mol of Gla/mol
of protein

Clotting timea

10 ⫾ 1
9.1 ⫾ 0.9
9.5 ⫾ 0.1
12.0 ⫾ 1
12.5 ⫾ 1
11 ⫾ 1
10.8 ⫾ 1
10.1 ⫾ 1
9.5 ⫾ 0.9
10 ⫾ 1
10.6 ⫾ 1
10.6 ⫾ 1.1

12.7 ⫾ 0.12
12.2 ⫾ 0.16
⬎120d
⬎120d
⬎120d
⬎ 120d
11.75 ⫾ 0.32
29.8 ⫾ 0.41
28.7 ⫾ 0.35
23.2 ⫾ 0.3
116.2 ⫾ 0.65
⬎120d

s

Rate of FII molecule cleavage by membrane-bound
fXa aloneb (nM FII consumed䡠sⴚ1䡠fXaⴚ1)

Rate of FII molecules cleavage by
prothrombinaseb (nM FII consumed䡠sⴚ1䡠fXaⴚ1)

0.13 ⫾ 0.03 (0.94)c
0.1 ⫾ 0.012 (0.99)
0.53 ⫾ 0.013 (0.99)
0.7 ⫾ 0.03 (0.98)
0.35 ⫾ 0.04 (0.99)
0.8 ⫾ 0.03 (0.99)
0.25 ⫾ 0.015 (0.99)
0.6 ⫾ 0.02 (0.99)
0.63 ⫾ 0.03 (0.99)
0.23 ⫾ 0.025 (0.98)
0.6 ⫾ 0.04 (0.99)
0.22 ⫾ 0.04 (0.95)

27.5 ⫾ 4.2 (0.99)c
22.8 ⫾ 3.8 (0.98)
1.0 ⫾ 0.26 (0.92)
1.5 ⫾ 0.34 (0.94)
1.3 ⫾ 0.09 (0.99)
1.8 ⫾ 0.12 (0.99)
24.9 ⫾ 4.6 (0.97)
28.8 ⫾ 2.8 (0.98)
18.2 ⫾ 3.7 (0.99)
35.9 ⫾ 3.8 (0.99)
1.23 ⫾ 0.12 (0.98)
1.84 ⫾ 0.15 (0.99)

a

Clotting times were determined using FII-deficient plasma as described under “Experimental Procedures” in quadruplicate.
The rates of rFII consumption were obtained following scanning densitometry of gels studying rFII activation. Some of the gels used are shown in Figs. 3–5. The final rate
of rFII consumption in the presence of membrane-bound fXa or prothrombinase was calculated using the apparent first-order rate constant, k (s⫺1), obtained directly from
the graph following plotting of the data as described under “Experimental Procedures.”
c
The numbers in parentheses represent the goodness of fit (R2) to the equation representing first-order exponential decay using the software Prizm from where the firstorder rate constant was obtained.
d
No clotting time could be detected following a 120-s incubation time period.
b

ilar effects observed with rFII⌬N10, rFII⌬C10, rFII⌬S5V,
rFIISLQ3AAA, and rFII⌬SLQ when studying rFII molecular
activation by membrane-bound fXa alone in the absence of
fVa (Fig. 4D and Table 1).
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

To improve our understanding of the essential role of amino
acids Leu480 and Gln481 for FII activation, we studied the pattern of all rFII molecules activation shown in Fig. 1 by fully
assembled prothrombinase (i.e. in the presence of an excess of
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. SDS-PAGE analyses of FIIplasma and rFII⌬473– 487 activation by membrane-bound fXa alone or prothrombinase. A, rFIIplasma (1.4 M) in the
presence of PCPS vesicles, DAPA, and membrane-bound fXa alone (5 nM). B, rFII⌬473– 487 (1.4 M) in the presence of PCPS vesicles, DAPA, and membrane-bound
fXa alone (5 nM). C, rFIIplasma (1.4 M) in the presence of PCPS vesicles, DAPA, and prothrombinase (1 nM fXa and 20 nM fVa). D, rFII⌬473– 487 (1.4 M) in the presence
of PCPS vesicles, DAPA, and prothrombinase (1 nM fXa and 20 nM fVa). Aliquots were withdrawn at various time intervals and treated as described (47, 69). M
represents the lane with molecular weight markers (from top to bottom): 98,000, 64,000, 50,000, and 36,000, respectively. Lanes 1–19 show samples from the
reaction mixture before (0 min) the addition of fXa and 20, 40, 60, 80, 100, 120, 150, 180, 210, and 240 s and 5, 6, 10, 20, 30, 60, 90, and 120 min, respectively, after
the addition of fXa. Following scanning densitometry as described under “Experimental Procedures,” the data representing FII consumption as a function of
time (s) were plotted using non-linear regression analysis according to the equation representing a first-order exponential decay and the rates of FII consumption using the apparent first-order rate constant, k (s⫺1), obtained directly from the fitted data, were calculated as described (47) and are reported in Table 1.
FII-derived fragments are identified to the right of A–D as follows: FII, prothrombin (amino acid residues 1–579); P1, prethrombin-1 (amino acid residues
156 –579); F1䡠2-A, fragment 1䡠2-A chain (amino acid residues 1–320); F1䡠2, fragment 1䡠2 (amino acid residues 1–271); P2, prethrombin-2 (amino acid residues
272–579); B, B-chain of IIa (amino acid residues 321–579); F1, fragment 1 (amino acid residues 1–155).
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fVa) by gel electrophoresis over a 2-h time period (Fig. 5). A
control experiment (Fig. 5A) demonstrates that under the conditions used, rFIIWT proceeds as its plasma counterpart following initial cleavage at Arg320, through the enzymatically active
intermediate meizothrombin, as confirmed by the appearance
of fragment 1䡠2-A. Rapid cleavage of this fragment at Arg271
leads to the formation of rIIa. Similar results were found when
using rFIIS478A (Fig. 5B) demonstrating that the S478A transition alone is of no consequence for timely FII activation by
prothrombinase. In contrast, activation of rFII⌬S5V and
rFIISLQ3AAA under similar experimental conditions was significantly delayed through the same pathway as verified by the
lingering of fragment 1䡠2-A at the late time points and the late
appearance of the B-chain of rIIa (Fig. 5, C and D). Similar
results were obtained with rFII⌬SLQ (Table 1). A systematic
analysis of the activation of all rFII mutant molecules by pro-
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thrombinase using similar experimental procedures, followed
by scanning densitometry of the gels and calculation of the rate
of rFII consumption, revealed the existence of two groups as
follows: a group of molecules represented by FIIplasma, rFIIWT,
and rFIIS478A (also containing rFIIL480A, rFIISL3AA, and
rFIISQ3AA) that are efficiently activated by prothrombinase;
and a second group of proteins represented by rFII⌬S5V and
rFIISLQ3AAA (including rFII⌬N10, rFII⌬C10, and rFII⌬SLQ) that
are activated by fully assembled prothrombinase with a rate
that is ⬃13–18-fold slower than the rate observed with rFIIWT
(Fig. 6A, inset, and Table 1). The data suggest that under conditions of saturating amounts of fVa with respect to fXa, the
dipeptide Leu480–Gln481 of prothrombin plays a leading role
during FII activation because it is required for fast and efficient
initial cleavage at Arg320 by prothrombinase (Fig. 6B, the deficient step is represented by the red arrow).
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 4. SDS-PAGE analyses of rFII molecule activation by membrane-bound fXa alone. A, rFIIWT (1.4 M) in the presence of PCPS vesicles, DAPA, and
membrane bound fXa alone (5 nM); B, rFII⌬S5V (1.4 M) in the presence of PCPS vesicles, DAPA, and membrane-bound fXa alone (5 nM). Aliquots were withdrawn
at various time intervals and treated as described (47, 69). M represents the lane with molecular weight markers (from top to bottom): 98,000, 64,000, 50,000, and
36,000, respectively. Lanes 1–19 show samples from the reaction mixture before (0 min) the addition of fXa and 20, 40, 60, 80, 100, 120, 150, 180, 210, and 240 s
and 5, 6, 10, 20, 30, and 60, 90, and 120 min respectively, after the addition of fXa. C, the two gels shown in A and B together with similar gels obtained with all
rFII studied were scanned, and rFII consumption was recorded as described under “Experimental Procedures.” Following scanning densitometry and normalization to the initial FII concentration, the data representing rFII consumption as a function of time (seconds) were plotted using non-linear regression analysis
according to the equation representing a first-order exponential decay using the software Prizm (GraphPad, San Diego). Prothrombinase was assembled with
rFIIWT (filled circles; R2 0.98), rFII⌬C10 (filled squares; R2 0.98), rFII⌬N10 (filled triangles; R2 0.99), rFII⌬S5V (filled inverse triangles; R2 0.99), rFIIS478A (filled diamonds; R2
0.99), rFIIL480A (open squares; R2 0.99), rFIISQ3AA (open circles; R2 0.98), rFIISL3AA (open triangles; R2 0.99), and rFIISLQ3AAA (open inverse triangles; R2 0.99). The rates
of rFII consumption shown in C, using the apparent first-order rate constant, k (s⫺1) obtained directly from the fitted data, were calculated as reported (47), and
the data are shown in Table 1. D, schematic representation of fragments derived following FII activation by membrane-bound fXa alone. The red arrow indicates
impaired cleavage at Arg320 in rFII⌬C10 (filled squares), rFII⌬N10 (filled triangles), rFII⌬S5V (filled inverse triangles), and rFIISLQ3AAA (open inverse triangles) resulting
in prethrombin-2 accumulation. FII-derived fragments are identified to the right of each panel, according to the description provided in the legend of Fig. 3.
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Kinetic Analyses of the Activation of rFII Molecules—To
understand the effect of the S478A/L480A/Q481A substitutions on the activity of prothrombinase in activating the rFII
molecules, we first examined the rates of rIIa formation from all
rFII molecules under similar experimental conditions. Historically, this method was designed to identify any deficiency in fVa
or fXa as part of prothrombinase in cleaving and activating FII
and is measured indirectly by using IIa generation as a reporting
probe with a chromogenic substrate. The comprehensive
kinetic data for several mutants are shown in Fig. 7 with the
kinetic constants derived directly from the fitted data reported
in Table 2. The combined findings demonstrate that whereas
the single and double alanine substitutions rFII mutants are
activated by prothrombinase similarly, providing kinetic constants comparable with the wild type or plasma FII molecules,
kinetic analyses of prothrombinase activation of rFIISLQ3AAA
demonstrate a modest 2.7-fold decrease in the kcat and a large
21-fold increase in the Km value of the reaction. Similar experiments studying rFII⌬SLQ activation by fully assembled prothrombinase revealed a 29-fold increase in Km with a concomitant 16-fold decrease in the kcat values of the reaction. A direct
comparison between the data obtained with rFIISLQ3AAA with
the data obtained with rFII⌬SLQ strongly suggest an important
contribution of the backbone structure of the peptide bond
between these three amino acids for efficient rFII activation by
prothrombinase.
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

To quantify the interaction between the two sets of double
mutations (S478A/L480A and S478A/Q481A) and to confirm
their apparent synergistic detrimental effect on prothrombinase function for activation of rFIISLQ3AAA, we have further
calculated the difference in free energy of the transition state
analog (⌬⌬Gint) for the triple mutant as described previously by
our laboratory (75, 76). The large positive value of ⌬⌬Gint (⫹2.4
kcal/mol) for the combination of the mutations at Leu480 and
Gln481 together with the sizable 55-fold decrease in the secondorder rate constant of prothrombinase for rFIISLQ3AAA activation signify that there is a deficiency in recognition between
prothrombinase and rFIISLQ3AAA. These findings solidify our
previous conclusion that these substitutions are detrimental to
the activation of rFII bearing the triple amino acid substitution
by fully assembled prothrombinase. However, it is important to
note that it is also possible that rIIaSLQ3AAA may also be deficient in its own catalytic activity as observed with rIIa⌬SLQ, and
the effect observed with rFIISLQ3AAA activation may be likewise due to the deficiency of rIIa in cleaving the chromogenic
substrate. Thus, although we cannot yet assign the poor performance of prothrombinase in cleaving rFIISLQ3AAA solely to a
deficiency in recognizing the mutated substrate, and because
the S478A transition is of no consequence for either rFIIS478A
activation or rIIaS478A activity, the overall data presented thus
far suggest that amino acid sequence Leu480–Gln481 may
have a dual effect in properly directing prothrombinase recJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. SDS-PAGE analyses of rFII molecule activation by prothrombinase. A, rFIIWT (1.4 M) in the presence of PCPS vesicles, DAPA, and prothrombinase
(1 nM fXa and 20 nM fVa). B, rFIIS478A same conditions as in A. C, rFII⌬S5V same conditions as in A. D, rFIISLQ3AAA same conditions as in A. Aliquots were withdrawn
at various time intervals and treated as described (47, 69). Same time points as described in the legend to Fig. 4. FII-derived fragments are identified to the right
of each panel, according to the description provided in the legend of Fig. 3.
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ognition of FII, as well as providing the resulting enzyme
with the appropriate surface required for proper substrate
tethering and cleavage. However, it is also possible that these
two amino acids are allosterically involved in both prothrombinase interactions with FII as well as the expression of
the enzymatic activity of IIa.
Analyses of the Activity of rIIa Molecules—Although many
investigations have identified the specific amino acid residues
from FII/IIa participating in either prothrombinase recognition
or IIa activity toward its physiological substrates, respectively,
few studies have shown that identical residues are involved in
both FII recognition by prothrombinase and IIa activity. To
understand the effect of the deletions/mutations on IIa activity,
we further assessed the amidolytic and biological activity of
selected rIIa molecules generated herein toward the chromogenic substrate S-2238 and toward thrombin’s natural substrates, fV, fVIII, and protein C.
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To understand the effect of the mutations on the amidolytic activity of IIa, we determined the kinetic constants for
the hydrolysis of S-2238 by the rIIa molecules under steady
state conditions. The data shown in Table 3 reveal the following: 1) rIIaWT produced under the conditions described
by our laboratory has similar activity as previously found
with other rIIaWT preparations, and 2) rIIaS478A has similar
catalytic efficiency (kcat/Km) as rIIaWT, as demonstrated previously (6, 86). In addition, we also found that whereas
rIIaSLQ3AAA was devoid of activity toward S-2238,
rIIaSQ3AA (where rIIaSQ3AA is recombinant human ␣thrombin with the mutation S478A/Q481A) has similar amidolytic activity as rIIaWT, whereas rIIaL480A and rIIaSL3AA (where
rIIaSL3AA is recombinant human ␣-thrombin with the mutation
S478A/L480A) are the most deficient in S-2238 hydrolysis among
the single and double alanine mutants when compared with
rIIaWT or rIIaS478A (Table 3). The combined data clearly demonstrate that amino acid Leu480 plays an important role during the
expression of IIa amidolytic activity and that the integrity of amino
acid sequence Leu480–Gln481 is required for optimal expression of
this activity.
The data shown in Figs. 8 and 9 demonstrate that whereas
rIIaWT and rIIaS478A cleave and activate fV and fVIII with similar rates (Figs. 8, A and C, and 9, A and C), rIIa⌬C10 (rIIa⌬C10
is recombinant human prothrombin missing amino acids
SVLQVVNLPI), and rIIa⌬S5V are totally deficient in cleaving
both cofactor molecules over a 3-h incubation period (Figs. 8, B
and H, and 9, B and H). These data are in complete agreement
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016

Downloaded from http://www.jbc.org/ at Cleveland State University on March 9, 2017

FIGURE 6. Analyses of the rates of activation of rFII by prothrombinase. A,
gels shown in Fig. 5, together with similar gels obtained with all rFII studied,
were scanned, and rFII consumption was recorded as described under “Experimental Procedures.” Following scanning densitometry, the numbers were
normalized to the initial concentration of rFII studied, and the data representing rFII consumption as a function of time (seconds) were plotted using nonlinear regression analysis according to the equation representing a first-order
exponential decay using the software Prizm (GraphPad, San Diego). rFIIWT
(filled circles; R2 0.98), rFII⌬C10 (filled squares; R2 0.99), rFII⌬N10 (filled triangles; R2
0.94), rFII⌬S5V (filled inverse triangles; R2 0.99), rFIIS478A (filled diamonds; R2 0.97),
rFIIL480A (open squares; R2 0.98), rFIISQ3AA (open circles; R2 0.99), rFIISL3AA (open
triangles; R2 0.99), and rFIISLQ3AAA (open inverse triangles; R2 0.99) are shown.
The inset shows the progress of the reaction during the first 180 s. The rates of
rFII consumption using the apparent first-order rate constant k (s⫺1),
obtained directly from the fitted data, were calculated as reported (47) and
shown in Table 1. B, schematic representation of fragments derived following
rFII activation by prothrombinase in the presence of excess fVa with respect
to fXa. The red arrow indicates impaired cleavage (at Arg320) in rFII⌬C10 (filled
squares), rFII⌬N10 (filled triangles), rFII⌬S5V (filled inverse triangles), and
rFIISLQ3AAA (open inverse triangles).

FIGURE 7. Determination of kinetic parameters of prothrombinase catalyzing cleavage and activation of various FII molecules. IIa generation
experiments were conducted as described under “Experimental Procedures”
by varying the substrate concentration and using a chromogenic substrate.
The solid lines represent the nonlinear regression fit of the data using Prizm
GraphPad software according to the Henri Michaelis-Menten equation (Vo ⫽
Vmax䡠[FII]/Km ⫹ [FII]) to yield the Km and kcat (kcat ⫽ Vmax/Etot, where Etot is the
concentration of fully assembled prothrombinase, in this case is 10 pM, Table
2). Prothrombinase activity with various rFII molecules is shown as follows:
rFIIWT filled circles; FIIPLASMA filled squares; rFIIS478A filled diamonds; rFIIL480A
open squares; rFIISL3AA open triangles; rFIISQ3AA open circles; rFIISLQ3AAA open
inverse triangles. Kinetic constants reported in the text and in Table 2 were
extracted directly from the fitted data shown herein.
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TABLE 2
Kinetic constants of plasma FII and various rFII mutant molecules activation by prothrombinase
FII species
FIIplasma
rFIIWT
rFIIWTe
rFII⌬473–487
rFII⌬N10
rFII⌬C10
rFII⌬S5V
rFIIS478A
rFIIL480A
rFIISL3AA
rFIISQ3AA
rFIISLQ3AAA
rFII⌬SLQe

Kma

kcata,b

M

min

0.13 ⫾ 0.02
0.11 ⫾ 0.015
0.11 ⫾ 0.02
NPf
NP
NP
NP
0.10 ⫾ 0.013
0.10 ⫾ 0.015
0.12 ⫾ 0.02
0.10 ⫾ 0.015
2.3 ⫾ 0.5
3.2 ⫾ 1.5

R2/points/titrationsc

⫺1

kcat/Km

Decreased

(M⫺1䡠s⫺1)䡠108

-fold

1992 ⫾ 68
1976 ⫾ 57
2054 ⫾ 84

0.93/30/3
0.97/20/2
0.97/10/1

2.5
2.9
3.1

1764 ⫾ 45
1630 ⫾ 49
1734 ⫾ 65
1727 ⫾ 52
730 ⫾ 101
128 ⫾ 34

0.97/20/2
0.96/20/2
0.92/30/3
0.94/30/3
0.96/36/4
0.96/9/1

2.9
2.7
2.4
2.9
0.053
0.0067

1.0
1.1
1.2
1.0
55
463

a

TABLE 3
Kinetic constants of wild-type and selected rIIa mutant molecules toward S-2238
␣-Thrombin species
rIIaWT
rIIaS478A
rIIaL480A
rIIaSL3AA
rIIaSQ3AA
rIIaSLQ3AAA

Kma

kcatb

M

⫺1

4.7 ⫾ 1.8
8.5 ⫾ 1.5
8.9 ⫾ 1.7
7.7 ⫾ 3.0
10.8 ⫾ 4.2
NPd

R2c

22.7 ⫾ 2.7
36.5 ⫾ 2.4
15.5 ⫾ 1.5
14.7 ⫾ 2.0
33.1 ⫾ 4.9
NP

kcat/Km
(M⫺1䡠 s⫺1)䡠106

s

0.93
0.98
0.98
0.92
0.93
NP

4.8
4.3
1.7
1.9
3.0

a

The Km value for S-2238 is listed for wild-type rIIa and selected rIIa mutants and determined as described under “Experimental Procedures” according to the MichaelisMenten equation using the software Prizm. Kinetic constants shown were derived directly from the fitted data.
b
kcat ⫽ Vmax/[enzyme]; the Vmax was calculated as described under “Experimental Procedures,” and the enzyme concentrations of rIIa was 4 nM for all experiments shown.
c 2
R is the goodness of fit of the data points to the Michaelis-Menten equation using the software Prizm.
d
NP is no plot; no data could be plotted to the Michaelis-Menten equation using the software Prizm.

with our findings shown in Table 1, explaining the fact that
rFII⌬C10 and rFII⌬S5V are devoid of clotting activity, and further
attest to the crucial dual role of the dipeptide Leu480–Gln481
during coagulation. Further analyses of the single or double
mutants reveal a slight differentiation in cleavage and activation
of the two cofactors by the various rIIa molecules. Although
rIIaL480A and rIIaSL3AA appear devoid of activity toward fV
(Fig. 8, D and E), both molecules slowly cleave fVIII at the
Arg372- and Arg1689-activating cleavage sites (Fig. 9, D and E)
(87–90). Similarly, although rIIaSLQ3AAA has no apparent activity
toward fV (Fig. 8G) over a 3-h time period, the mutant enzyme
cleaves fVIII slowly at the non-activating Arg740 cleavage site (Fig.
9G). Finally, although rIIaSQ3AA cleaves fV efficiently at Arg709 to
produce the heavy chain of fV and an Mr 220,000 intermediate
(Fig. 8F), the enzyme is also efficient in cleaving fVIII at the
Arg372- and Arg1689-activating cleavage sites (Fig. 9F). These
two cofactors have strategic functions within the amplified
coagulation response to vascular damage and must be activated
to perform accordingly within their respective enzymatic complexes. The combined data explain the impaired procoagulant
activity of rFIISLQ3AAA (Fig. 2), which is deficient in producing
large amounts of rIIa in a timely fashion (Fig. 5D). However,
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

even when rIIaSLQ3AAA is generated, the recombinant enzyme is
deficient in activating the pro-cofactors.
We next assessed the capability of the rIIa molecules in the presence of thrombomodulin to activate protein C and produce APC.
Fig. 10 shows the results of such an experiment and demonstrates
that although rIIa⌬S5V (rIIa⌬S5V is recombinant human ␣-thrombin with region SVLQV deleted) cannot cleave and activate protein C, rIIaSLQ3AAA has small but significant activity generating
minute amounts of APC (Fig. 10, lanes 8 and 9), which in turn can
cleave fV at Arg506/Arg306 and produce the characteristic Mr 30,000
fragment (data not shown) (68, 91). All other rIIa mutant molecules
tested,forAPCgeneration,havesimilaractivitiesasrIIaWT orplasmaderived IIa under the condition described (Fig. 10).
These data demonstrate a differential requirement of IIa for
cleavage and activation of both the pro-cofactor molecules and
protein C and attest to the sensitive requirements of fV for
cleavage and activation by IIa. Overall these results demonstrate that amino acids Leu480 and Gln481 within the serine
protease domain of FII serve a dual purpose, and thus both are
required for efficient cleavage at Arg320 by prothrombinase and
may be involved in the presentation of an obligatory exosite for
timely fV, fVIII, and protein C activation by IIa.
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The Km and kcat values of prothrombinase assembled with saturating concentrations of recombinant fVa molecules were determined as described under “Experimental Procedures” according to the Michaelis-Menten equation using the software Prizm with several different preparations of rFII molecules (representative experiments are shown
in Fig. 7). Kinetic constants were derived directly from the fitted data.
b
kcat ⫽ Vmax/[enzyme]; the enzyme concentration of prothrombinase (fXa䡠fVa complex on the membrane surface in the presence of Ca2⫹) under the conditions employed
herein was 10 pM.
c 2
R is the goodness of fit of the data points to the Michaelis-Menten equation using the software Prizm. Points and titrations studied represent 10 measurements/graph for
all experiments (up to 4 M plasma-derived FII or rFII molecules) except experiments with rFIISLQ3AAA (nine measurements/graph, up to 2 M prothrombin) and with
rFII⌬SLQ (nine measurements/graph, up to 4 M prothrombin).
d
The -fold decrease is the ratio of the second-order rate constant (kcat/Km) of prothrombinase catalyzing rFIIWT activation compared with the second-order rate constant of
prothrombinase catalyzing activation of all other rFII molecules.
e
Experiments with these two preparations of recombinant molecules were performed in parallel with same reagents (fXa and PCPS vesicles). The results shown are representative of four separate titrations with three different preparations of rFII⌬SLQ compared with either rFIIWT or FIIplasma.
f
NP is no plot; data could not be plotted to the Michaelis-Menten equation using the software Prizm.
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Discussion
Our data demonstrate that amino acid region 473–487 of FII is
required for timely activation of FII through the meizothrombin
pathway. Although prior work using synthetic peptides suggested
that this region of the cofactor may contain an fVa-dependent
fXa-binding site for FII, the data presented herein with recombinant FII molecules provide for the first time a mechanistic interpretation of these findings and identify the crucial amino acids
from this sequence responsible for the effect observed (56).
To elucidate the number and identity of the required amino
acids within amino acid sequence 473– 487 of FII, we constructed, expressed, purified to homogeneity, and studied several rFII molecules with deletions and point mutations within
this important regulatory region. We first investigated the
effects of the 15-amino acid deletion with rFII⌬473– 487, followed
by experiments with rFII molecules containing overlapping
deletions within this segment (rFII⌬N10 and rFII⌬C10 and
rFII⌬S5V and rFII⌬SLQ). Several rFII molecules bearing single
mutations (rFIIS478A and rFIIL480A), double mutations
(rFIISL3AA and rFIISQ3AA), and a triple mutation
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(rFIISLQ3AAA) were subsequently made. Membrane-bound
fXa cleaves FII sequentially at Arg271 followed by Arg320, forming small amounts of IIa. Under these conditions, the activation
of the deletion mutants rFII⌬473– 487, rFII⌬N10, rFII⌬C10,
rFII⌬S5V, the triple alanine mutant, and the deletion mutant
(rFIISLQ3AAA and rFII⌬SLQ) resulted in a modest increase of the
rate of activation. In addition, activation of these six rFII molecules
by fXa alone resulted in accumulation of prethrombin-2, with very
little IIa formed. In contrast, activation of all these rFII mutants by
fully assembled prothrombinase is significantly delayed. The combined data suggest that amino acids Leu480 and Gln481 within
region 473– 487 of FII either represent or are responsible for the
presentation of an fVa-dependent site for fXa on FII, which is essential for optimal rate of cleavage at Arg320, which in turn is required for
timely IIa formation at the place of vascular injury.
The autolysis loop of APC bears strong homology with the
FII sequence 473– 487 (chymotrypsin numbering 149D-163)
(92). Replacement of several basic amino acids from this homologous region in APC by site-directed mutagenesis to alanine
demonstrated the ability of this exosite to interact with its subVOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 8. Activation of plasma-derived fV by rIIa. Plasma-derived fV (500 nM) was incubated with rIIa (4 nM) as described under “Experimental Procedures.” At
selected time intervals, aliquots of the mixtures were removed, mixed with 2% SDS, heated for 5 min at 90 °C, and analyzed on a 4 –12% SDS-PAGE followed by staining
with Coomassie Blue. Lane 1 in all panels depicts aliquots of the mixture withdrawn from the reaction before the addition of rIIa. Lanes 2– 8 represent aliquots of the
reaction mixture withdrawn at 10, 20, 30, 45, 60, 120, and 180 min. The positions of all fV fragments and of the heavy (HC) and light chains (LC) of the active cofactor are
indicated on the right. Fragments a and b of fV are identified as previously described (80). The rIIa molecule used each time is indicated under each panel.

Function of Sequence Leu480–Gln481 of Prothrombin

strate fVa and to differentiate between the Arg506 and Arg306
cleavage sites (93). Yegneswaran et al. (56) using synthetic peptides provided initial evidence that sequence 473– 487 of FII is
able to disrupt prothrombinase assembly only in an fVa-dependent manner. Chen et al. (50) identified a sequence within proexosite I of prothrombin containing basic residues Arg35, Lys36,
Arg67, Lys70, Arg73, Arg75, and Arg77 (chymotrypsin numbering), which is in close spatial proximity to region 473– 487 of
FII. These investigations revealed that following replacement of
all basic residues from pro-exosite I with Glu, there was a significant effect on fXa within prothrombinase when compared
with fXa alone in cleaving and activating FII, suggesting that
these amino acids are specific fVa-dependent recognition sites
for fXa on FII. Further kinetic studies by Chen et al. (50) using
the hirudin COOH-terminal peptide (hirugen) showed that the
peptide inhibited wild type prethrombin-1 activation by prothrombinase, whereas hirugen had no inhibitory effect on the
activation of the mutated zymogen lacking the basic residues in
pro-exosite I by fXa alone. The combined studies of Chen et al.
(50) and Yegneswaran et al. (56) suggest the requirement of
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

both sites for optimum productive interaction of prothrombinase with FII and timely IIa formation.
Research with discontinuous assays using a chromogenic
substrate for IIa revealed that when fVa is incorporated into the
prothrombinase complex, the resulting Km value of the reaction
was decreased by 100-fold (corresponding to a 100-fold increase in affinity of prothrombinase for FII as compared with
the affinity of fXa alone for the substrate), whereas the catalytic
efficiency (kcat) of fXa was increased by 3,000-fold resulting in a
300,000-fold overall increase in the activity of prothrombinase
(second-order rate constant) for FII compared with the activity
of fXa alone toward FII (16). The significant increase in affinity
of prothrombinase for its substrate is attributed to tighter binding of the enzymatic complex to FII because of its localization
on the membrane surface by fVa. The longstanding hypothesis
that fVa “localizes and positions” FII in an optimum position for
efficient catalysis by fXa consistent with the classical role of a
cofactor for catalysis was recently confirmed by computational
studies with prothrombinase by Shim et al. (27). These studies
demonstrated that the acidic COOH-terminal portion of the
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 9. Activation of recombinant fVIII by rIIa. rfVIII (500 nM) was incubated with rIIa (4 nM) as described under “Experimental Procedures.” At selected time
intervals, aliquots of the mixtures were removed, mixed with 2% SDS, heated for 5 min at 90 °C, and analyzed on a 4 –12% SDS-PAGE followed by staining with
Coomassie Blue. Lane 1 in all panels depicts aliquots of the mixture withdrawn from the reaction before the addition of rIIa. Lanes 2– 8 represent aliquots of the
reaction mixture withdrawn at 10, 20, 30, 45, 60, 120, and 180 min. The positions of all rfVIII fragments are indicated on the right. Fragments from rfVIII are
identified as previously demonstrated (80). The rIIa molecule used each time is indicated under each panel.
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heavy chain of fVa that is contiguous to the A2 domain of fVa is
essential in its ability to interact and snare the serine protease
domain of FII. In that manner, this acidic amino acid sequence
reposition the Arg320 cleavage site at an optimum position for
timely cleavage by fXa and FII activation at the site of vascular
injury as earlier suggested (54) and more recently experimentally demonstrated by our laboratory with synthetic peptides
and recombinant fVa molecules mutated at these specific sites
(45, 47, 48).
We show that following removal of the amino acid sequence
473– 487 from FII, prothrombinase loses the ability to efficiently form IIa because of impaired fVa-dependent cleavage of
FII by fXa at Arg320. One easy explanation of these results was
that elimination of such a huge portion of the molecule results
in significant structural changes of the molecule that in turn
have deleterious effects on FII molecular conformation resulting in deficient prothrombinase activity. Despite the fact that
rFII⌬473– 487 was activated following the same pathways as
rFIIWT in the presence or absence of fVa, albeit with different
rates, and in the absence of a crystal structure of rFII⌬473– 487,
there was still doubt about the structural integrity and function
of a molecule bearing such a large deletion. Experiments using
more modest overlapping deletions (with rFII⌬N10, rFII⌬C10,
and rFII⌬S5V) as well as with a triple alanine mutant
(rFIISLQ3AAA) and a triple deletion mutant (rFII⌬SLQ) demonstrated that these molecules are also hindered in their fVa-dependent cleavage at Arg320 to a similar level as rFII⌬473– 487
(Table 1 and Fig. 6). These data provide original evidence demonstrating that the minimal sequence of FII required for the
3,000-fold increase in the catalytic efficiency of prothrombinase, as defined ⬃36 years ago (16) for efficient cleavage of FII
by prothrombinase at Arg320, is carried at least partially by
amino acid sequence Leu480–Gln481 of FII. The findings presented herein silence the notion that the effect seen with
rFII⌬473– 487 may be due to a structural change of the mutant
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FIGURE 10. Activation of protein C by rIIa. Plasma-derived protein C (80 nM)
was incubated with rIIa (8 nM), thrombomodulin, and PCPS as described
under “Experimental Procedures.” Following a 3-h incubation period, each
individual solution was dried with a vacuum concentrator, resuspended in
Tris buffer, mixed with 2% SDS and 2% ␤-mercaptoethanol, heated for 5 min
at 90 °C, and analyzed on a 5–15% SDS-PAGE followed by staining with Coomassie Blue. Lane 1, protein C alone no IIa; lane 2, protein C alone, no IIa
incubated with buffer for 3 h; lane 3, protein C and rIIa⌬S5V; lane 4, protein C
and plasma-derived IIa; lane 5, protein C and rIIaWT; lane 6, protein C and
rIIaS478A; lane 7, protein C and rIIaL480A; lane 8, protein C and rIIaSL3AA; lane 9,
protein C and rIIaSQ3AA; and lane 10, protein C and rIIaSLQ3AAA. Positions of
protein C and APC heavy and light chain fragments are indicated at the right
(a/b heavy chains, and c light chain). The two heavy chains of protein C in
plasma (a and b) have been identified earlier, differ by one glycosylation site,
and have been extensively studied (58, 59).

molecule rather than to specific amino acid(s) missing from
rFII⌬473– 487.
The kinetic findings presented herein revealed comparable
Km and kcat constants for prothrombinase when rFII molecules
bearing the single and double alanine mutations were used as
substrate. However, when rFIISLQ3AAA was the substrate for
prothrombinase in the same discontinuous assay, there was a
significant 21-fold increase in the Km value and a modest 2.7fold decrease in the kcat of the enzyme. Similar results were
obtained with rFII⌬SLQ. Furthermore, rFIISLQ3AAA and
rFII⌬SLQ were also found to be substantially deficient in clot
formation in an assay using FII-deficient plasma, whereas
rIIaSLQ3AAA was also deficient in S-2238 hydrolysis.
rIIaSLQ3AAA was also impaired in cleaving fV, fVIII, and to a
lesser extent protein C. These data dovetail nicely with results
obtained with rIIa⌬S5V and rIIa⌬473– 487. We can thus hypothesize that the substantial increase in the Km of prothrombinase
toward rFIISLQ3AAA is due to a deficiency in prothrombinase in
recognizing the mutant molecule because of the lack of Leu480–
Gln481, whereas the decrease in enzymatic activity of the resulting rIIaSLQ3AAA molecule is also the result of the absence of
these two important amino acid side chains. Additional data
with rFII⌬SLQ provide further evidence of the crucial role of amino
acids Leu480–Gln481 and the peptide bond backbone between
these two amino acids because, when these residues are completely eliminated, the Km value of the reaction increases by
32-fold, and the kcat value decreases by 16-fold (Table 2). Keeping
in mind that the S478A substitution is of no consequence on both
rFII activation and rIIa function, these results provide strong evidence in favor of the dual role of amino acids Leu480 and Gln481.
Moreover, these amino acids are required by prothrombinase to
efficiently promote cleavage of FII at Arg320 and are also required
by IIa for optimum amidolytic activity as well as to proficiently
cleave and activate fV, fVIII, and protein C. Finally, the possibility
that elimination of these two residues from rFII results in an allosteric transition of the amino acids around/within the active site of
rIIa, thus modifying the critical distances between the specific residues of the catalytic triad resulting in impaired catalysis, cannot be
eliminated.
A comparison of crystal structures of FII, meizothrombin,
IIa, prethrombin-1, and prethrombin-2 was carried out to identify structural differences in/near the Gly473–Ile487 segment
comprising the fVa-dependent fXa-binding site. These residues
adopt similar conformations in all of the crystal structures, with
the NH2-terminal residues Gly473–Gln476 being quite solventaccessible or flexible, and residues Pro477–Ile487 being variable
in their degree of solvent exposure. Residue Ile487 is significantly more exposed in prothrombin (accessible surface area of
⬎30 Å2 compared with ⱕ10 Å2 in meizothrombin and thrombin), as well as the adjacent Pro486 (accessible surface area of
⬃15–30 Å2 reducing to ⬍10 Å2 in meizothrombin and thrombin). The amount of solvent exposure of Ile487 and Pro486
appears to be heavily influenced by the flanking loops encompassing residues Ala446–Tyr454 and Lys511–Ser525, which adopt
different conformations upon FII activation (Fig. 11). Recently,
Pozzi et al. (94) used the crystal structure of Gla-domainless FII
with active site S525A to demonstrate that fVa has recognition
sites in close proximity to Arg320 (Arg15 chymotrypsin number-
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solvent-exposed in both FII and IIa. The Ser478/Leu480/Gln481
residues are near ABE-I (Fig. 11), but ⬎15 Å from the catalytic
Ser525 residue, and even more distant from ABE-II.
In conclusion, in this study we provide evidence for the dual
effect of amino acids Leu480 and Gln481 of FII. Future mutagenesis studies within the amino acids uncovered herein, paired
with selected mutations within pro-exosite-I and/or pro-exosite-II of FII, should be able to elucidate the intermolecular
communications within FII, required for both optimal fVa-dependent activation of FII and subsequent IIa catalytic activity
toward its numerous physiological substrates. Finally, our
results provide evidence for the production of large quantities
of rFII⌬S5V, rFIISLQ3AAA, or rFII⌬SLQ that could be used as
therapeutic agents because these molecules would compete
with the natural substrate in vivo, when infused in individuals
with prothrombotic tendencies.

FIGURE 11. Location of exosites in FII and thrombin structures. Representation of the high resolution crystal structures of FIIWT (A) and IIa (B). A, spacefilling representation of human FII (38). Residues Ser478, Leu480, and Gln481 are
colored green; ABE-I and ABE-II residues (6, 50) are purple-blue and yellow,
respectively; the amino acids composing the catalytic triad are not solventaccessible and thus not visible. Other catalytic domain residues are in light
gray, and those in fragment-1 and fragment-2 are in dark gray. B, space-filling
representation of IIa (81). Residues are colored as for FII with the addition of
catalytic triad residues His363, Asp419, and Ser525 (red), which are partially solvent-accessible. In parentheses are the corresponding numbers according to
the chymotrypsin numbering of IIa (4). Distances between the active Ser525
side chain hydroxyl and several other amino acids of interest are as follows: 17
Å to Gln481 OE1/NE2; 15 Å to Glu549 OE1; 17 Å to Arg382 NH2; 18 Å to Lys385 NH2.
The polar atoms at the end of the side chains were used as a reference
because these would presumably be involved in intermolecular interactions.

ing). These sites create a strong electrostatic potential due to a
number of basic residues described by Chen et al. (50). Through
analysis of this published crystal structure, we have located this
basic region to be in the vicinity of the Leu480–Gln481 amino
acid sequence of FII that we found to be required for efficient
initial cleavage at Arg320 by prothrombinase. It is noteworthy
that a very recent study by Pozzi et al. (38) demonstrated a
crucial role for linker 2 for the rate of activation of FII by prothrombinase and suggested that this region may be involved in
the interaction of FII with the cofactor. These data are in complete accord with data showing that fragment 1, more precisely
the kringle 2 region, is involved in the interaction of fVa as part
of prothrombinase with FII (39, 41). Finally, a close comparison
of crystal structures of FII and IIa revealed that residues Ser478,
Leu480, and Gln481 adopt similar conformations in both structures. The Ser478 side chain is exposed on the surface of both
molecules, whereas the Leu480 side chain is surrounded by
other residues and is not accessible to solvent. Gln481 is partially
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4
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